...
首页> 外文期刊>European Journal of Haematology >Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation
【24h】

Impact of CD34+ cell dose on reduced intensity conditioning regimen haploidentical hematopoietic stem cell transplantation

机译:CD34 +细胞剂量对强度调理方案造血干细胞移植降低的影响

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Abstract Objectives Haploidentical hematopoietic stem cell transplant (haplo‐SCT) has been associated with higher rates of graft rejection, and a higher dose of CD34+?cell dose is frequently requested. We aim to explore the impact of CD34+?cell dose in peripheral blood stem cell (PBSC) grafts using reduced intensity conditioning (RIC) in haplo‐SCT. Methods Sixty‐eight consecutive haplo‐SCT in adult patients were included. Graft‐vs‐host disease (GVHD) prophylaxis consisted on ATG, PTCy, and CsA. The cohort was divided in two groups using CD34+?dose of?≥?9?×?10 6 CD34+/Kg as cutoff point. Median follow‐up was 8.9?months. Results Median cell dose infused was 9.32?×?10 6 CD34+/Kg. Forty (58.8%) recipients received grafts with CD34+?cells ≥9?×?10 6 /kg. The infusion?≥?9?×?10 6 CD34+/Kg cell dose had a negative impact in overall survival ( P ?=?.03) after adjusting for age at transplant. The cumulative incidence of acute GVHD and graft failure were not significantly influenced per CD34+?cell dose. Only four recipients had grade III aGVHD, and all of them received grafts with a CD34+?cell dose?≥?9?×?10 6 . Conclusion In RIC haplo‐SCT, recipients may not benefit from PBSC grafts with a CD34+/kg cell dose higher than 9?×?10 6 cells/kg, as it can have an adverse impact in post‐transplant outcome.
机译:摘要目的杂草造血干细胞移植(HAPLO-SCT)已经与较高的接枝抑制率相关,并且经常要求较高剂量的CD34 +细胞剂量。我们的目标是在HAPLO-SCT中使用降低的强度调理(RIC)来探讨CD34 +?细胞剂量在外周血干细胞(PBSC)移植物中的影响。方法包括成年患者六十八条连续的HAPLO-SCT。移植物 - 宿主疾病(GVHD)预防组合在ATG,PTCY和CSA上。使用CD34 +的群组分为两组α≥?9?×10 6 CD34 + / kg作为截止点。中位后续时间为8.9?几个月。结果中位细胞剂量注入为9.32?×10 6d34 + / kg。四十(58.8%)接受者接受了CD34 +的移植物≥9?×10 6 / kg。输注≥1?9?×10 6 CD34 + / kg细胞剂量在移植期间调整年龄后,在整个存活(P?=β.03)中具有负面影响。急性GVHD和接枝衰竭的累积发病率未受CD34 +?细胞剂量的显着影响。只有四名受者有III级AGVHD,所有这些接受者都接受了CD34 +?细胞剂量的移植物(细胞剂量)?≥≤9?×10 6。结论在RIC HAPLO-SCT中,接受者可能无法从PBSC移植物中受益于高于9?×10 6个细胞/ kg的CD34 + / kg细胞剂量,因为它可以对移植后结果产生不利影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号